2 February, 22

Press Release

Syz Capital partner with Saturnus Capital to take controlling stake in leading German Pharmaceutical Logistics firm, SK Pharma

SK Pharma is one of Germany’s leading pharmaceutical pre-wholesalers. Syz Capital is a boutique private markets investor providing exclusive access to niche investments in private equity and alternative investments. Saturnus Capital is a private equity firm focused on mid-market transactions in the DACH region.

Syz Capital, the boutique private markets investment specialist, announced today that it has taken a controlling stake in SK Pharma Logistics, specialized in storing, handling, repackaging and distributing pharmaceutical products. Backed by the Syz Family and in close partnership with Saturnus Capital, Syz Capital is looking to grow and accelerate the expansion of this strong market leader, bringing it to new heights. Based in Bielefeld, Germany, SK Pharma is a family-owned business servicing both European and Global pharmaceutical companies. A leader in the space, the company specializes in pharmaceutical and medical grade products, as well as cosmetics and dietary products. The company offers the entire value chain of logistics, offering its customer turnkey solutions. The company has been growing impressively, averaging a CAGR of 28% in the last 3 years, 7x faster than the healthcare industry in Germany over the last 10 years. The firm expects further growth as the regulatory environment is becoming stricter and the underlying industry is forecasted to grow consistently over the next few years. Marc Syz, Managing Partner of Syz Capital, says: “We believe there is a unique opportunity to help this entrepreneurial family business expand its business and footprint organically and by acquisition, consolidating the relatively fragmented sector serving global customers. With SK Pharma, we truly have found another hidden champion which offers a strong platform to drive future value creation.” “The deal also demonstrates the potential value creation we can add to our clients’ portfolios and underlines how Syz Capital is unlocking unique synergistic opportunities in the private equity and alternatives space.” Joscha Boehm, Managing Partner of Saturnus Capital, and Philipp Schweizer, Partner of Saturnus Capital, who teamed up with Syz Capital for this transaction commented: “We are excited to be closely working with the founders and the management team to further develop SK Pharma in the coming years. We consider SK Pharma to be a well-run business that is uniquely positioned to continue to grow and gain market share.” This acquisition marks another important milestone for Syz Capital in the family businesses landscape. Both Saturnus and Marc Syz will join the SK Pharma Board of Directors along the Krone family and Philippe Milliet, a former Galenica executive and industry veteran. Stephan Krone, CEO of SK Pharma Logistics GmbH, added: “We believe Syz Capital and Saturnus Capital are ideal partners with significant experience investing in family-owned businesses to drive SK Pharma through its next growth phase and beyond, to create value for our customers and partners. They have a clear growth strategy for the future, the management team and myself are excited to partner with them and, together, build SK Pharma into a leading European player in the Pharma Logistics Industry.”
October 30, 2025

Dynamics of the liquidity slowdown in Private Equity

Exploring the key drivers behind the recent decline in PE exit activity
October 30, 2025

Hedge Funds on a Winning Streak, What’s Next for 2025?

Strong second half in 2024 to close a remarkable year for Hedge Funds. Equity Hedge managers have thrived thanks to healthy sector dispersion. No signs of slowdown ahead. While Merger Arbitrage faced regulatory issues Event-Driven overall benefitted from market strength. Discretionary macro capitalized on divergent policies and global shifts, while Systematic strategies lagged. Relative Value managers sailed through a flawless year with tailwinds still in their favor. Digital asset strategies have outpaced the broader hedge fund industry while shielding investors from crypto volatility.
July 11, 2025

Riding the waves of dispersion

Global markets saw mixed but ultimately positive performance in H1. January opened strong, driven by policy shifts and gains in energy, healthcare, and European equities. February and March were volatile as trade tariff concerns weighed on sentiment, with US tech leading losses and growth stocks sharply underperforming value. Interest rates fell globally early in the period, except for the US where the Dollar fluctuated, and commodities were mixed. April brought heightened volatility but improved sentiment by month-end, with renewed optimism around trade negotiations and potential rate cuts. May saw a strong rebound, led by technology and improving global growth prospects, with Germany and Japan topping regional equity gains. Overall, risk appetite recovered heading into summer.